• Home
• Services
• Bioconjugate Drug Development & Manufacturing
• Oligo Based Drug Conjugate

Oligo Based Drug Conjugate

CellMosaic® offers bioconjugation research and development services for biopharmaceutical companies focused on antisense and siRNA-based therapeutics.

One of the major challenges in developing oligonucleotide analogs and siRNA therapeutics is their limited cellular uptake, poor in vivo pharmacokinetics, and lack of specificity for target tissues or cells. Recent studies have shown that chemically conjugating oligonucleotide analogs and siRNAs to bioactive molecules, lipids, or polymers can overcome many of these limitations.

CellMosaic® prepares oligo-based conjugates using unique conjugation strategies developed in-house. PEG or other classical polymers can be attached at any position on the oligo—3', 5', or through a modified base—either during solid-phase synthesis or in the post-synthesis solution phase. In most cases, a single pure conjugate can be obtained.

Advantages of CellMosaic's conjugation strategy:

• Freedom to attach a drug or molecule of interest at any point on the oligo.
• Other functional groups (e.g., OH, NH₂, and SH) remain unaffected during conjugation.
• Conjugation strategies can be readily adapted for different categories of compounds.
• Short development timeline for designing a customized conjugation strategy. 

Case Studies:

1. Delivery of antisense oligonucleotides with poly K peptide (oligo-peptide conjugate synthesized at CellMosaic®): peptide and oligo are linked together through a thiol ether bond. The conjugate has a characteristic UV spectrum of polyK peptide (205 nm) and oligo (260 nm).